Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
Biotech
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

For a Chinese cancer drug developer, Bristol-Celgene deal is poised to have big ripple effects

  • Rebecca Robbins

By Rebecca Robbins Feb. 13, 2019

Reprints
John V. Oyler, CEO of BeiGene
BeiGene CEO John Oyler Imaginechina via AP

SAN FRANCISCO — Celgene is famous for cultivating a constellation of biotech partners — companies whose fortunes are poised to be shifted by last month’s news that Bristol-Myers Squibb plans to buy Celgene in a $74 billion deal.

One of those partners is BeiGene, among the buzziest companies in China’s rising biotech sector and one that could feel ripple effects.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Rebecca Robbins

Rebecca Robbins

Health Tech Correspondent

Rebecca covers health technology. She is the co-author of the newsletter STAT Health Tech.

Tags

The X-waiver for buprenorphine prescribing is gone. It’s time…
The X-waiver for buprenorphine prescribing is gone. It’s time to spread the word
New on the streets: Gabapentin, a drug for nerve…
New on the streets: Gabapentin, a drug for nerve pain, and a new target of misuse
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
California judge deals GSK a setback as first Zantac…
California judge deals GSK a setback as first Zantac lawsuit will now go to trial
Up and down the ladder: The latest comings and…
Up and down the ladder: The latest comings and goings
Pharmalittle: EU delays pharma legislation again; India cancels license…
Pharmalittle: EU delays pharma legislation again; India cancels license for maker of cough syrup linked to…

Recommended Stories